Leriglitazone clinical trials
Also written MIN-102.
How each study uses leriglitazone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 21 Sept 2026 · Nezglyal · EMEA/H/C/006693 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Minoryx Therapeutics, S.L. (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test leriglitazone, phase 3 first.
- May 2027A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral AdrenoleukodystrophyPhase 3 · Minoryx Therapeutics, S.L.
Studies
Open first, then newest update. How each study uses leriglitazone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN PatientsCompletedPhase 2/3Minoryx Therapeutics, S.L.NCT03231878Written as Leriglitazone
- A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral AdrenoleukodystrophyActive, not recruitingPhase 3Minoryx Therapeutics, S.L.NCT05819866Written as Leriglitazone
- A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)Status unknownPhase 2Minoryx Therapeutics, S.L.NCT04528706Written as MIN-102
- A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female PatientsCompletedPhase 2Minoryx Therapeutics, S.L.NCT03917225Written as MIN-102
Codes
What other systems call leriglitazone · ClinicalTrials.gg INT001747
- MeSH (NLM) C000720427leriglitazoneOne source NLM
- UNII (FDA) K824X25AYALERIGLITAZONEConfirmed FDA, NLM
- NCI Thesaurus C170108LeriglitazoneOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720427 | leriglitazone | One source NLM |
| UNII (FDA) | K824X25AYA | LERIGLITAZONE | Confirmed FDA, NLM |
| NCI Thesaurus | C170108 | Leriglitazone | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.